SCHEMBL25773177

SCHEMBL25773177

CCN(CC)S(=O)(=O)c1ccc(SC)cc1

nearest known ligand 0.66

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ LMNA P02545 5/20 0.66
▸ HTT P42858 4/20 0.66
▸ SMN1; SMN2 Q16637 3/20 0.66
▸ NPC1 O15118 1/20 0.59
▸ RAB9A P51151 1/20 0.59
▸ ALDH1A1 P00352 7/20 0.54
▸ GAA P10253 1/20 0.54
▸ MEN1 O00255 1/20 0.51
▸ KMT2A Q03164 1/20 0.51
▸ L3MBTL1 Q9Y468 1/20 0.51
▸ TAS2R14 Q9NYV8 1/20 0.51
▸ KDM1A O60341 1/20 0.50
▸ MAOA P21397 1/20 0.50
▸ MAOB P27338 1/20 0.50
▸ MAPT P10636 1/20 0.49
▸ TSHR P16473 1/20 0.49
▸ TP53 P04637 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5023540 0.78 HTT (0.73) LMNAHTTSMN1; SMN2NPC1RAB9A
SCHEMBL23057256 0.78 LMNA (0.73) LMNAHTTSMN1; SMN2NPC1RAB9A
SCHEMBL10592845 0.78 LMNA (0.73) LMNAHTTSMN1; SMN2NPC1RAB9A
SCHEMBL765375 0.78 ALDH1A1 (0.55) LMNAHTTSMN1; SMN2NPC1RAB9A
SCHEMBL3314209 0.76 LMNA (0.70) LMNAHTTSMN1; SMN2NPC1RAB9A
SCHEMBL810965 0.76 LMNA (0.70) LMNAHTTSMN1; SMN2NPC1RAB9A
SCHEMBL4069104 0.76 LMNA (0.70) LMNAHTTSMN1; SMN2NPC1RAB9A
SCHEMBL2914696 0.76 HTT (0.70) LMNAHTTSMN1; SMN2NPC1RAB9A
SCHEMBL23043651 0.76 LMNA (0.70) LMNAHTTSMN1; SMN2NPC1RAB9A
SCHEMBL2932439 0.76 LMNA (0.70) LMNAHTTSMN1; SMN2NPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230212122-A1 MITOCHONDRIAL TARGETING COMPOUNDS FOR THE TREATMENT OF ASSOCIATED DISEASES NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2023-07-06 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230212122-A1 MITOCHONDRIAL TARGETING COMPOUNDS FOR THE TREATMENT OF ASSOCIATED DISEASES TFAM, CS, FH LMNA 2208/4885HTT 847/4885SMN1; SMN2 646/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback